dc.contributor.author
Martínez Yélamos, Antonio
dc.contributor.author
Saiz Hinarejos, Albert
dc.contributor.author
Sánchez del Valle Díaz, Raquel
dc.contributor.author
Casado Ruiz, Virginia
dc.contributor.author
Ramon Torrell, Josep M. (Josep Maria)
dc.contributor.author
Graus Ribas, Francesc
dc.contributor.author
Arbizu Urdiain, Txomin
dc.date.issued
2020-04-24T11:17:43Z
dc.date.issued
2020-04-24T11:17:43Z
dc.date.issued
2001-08-28
dc.date.issued
2020-04-24T11:17:43Z
dc.identifier
https://hdl.handle.net/2445/157307
dc.description.abstract
Axonal damage probably occurs early in the evolution of MS. Five of 38 (13%) patients had a positive assay for the neuronal 14-3-3 protein in the CSF obtained at the first clinically isolated syndrome suggestive of MS. A positive 14-3-3 assay was the only independent predictor for a shorter time to conversion to clinical definite MS (risk ratio 4.1; 95% CI 1.1 to 15) and to reach an Expanded Disability Status Scale (EDSS) > or =2 at the end of follow-up (odds ratio 14.8; 95% CI 2.86 to 76.8). The detection of the 14-3-3 protein in the CSF at the first neurologic event suggestive of MS may be a useful predictor of short-term evolution.
dc.format
application/pdf
dc.publisher
Lippincott, Williams & Wilkins. Wolters Kluwer Health
dc.relation
Reproducció del document publicat a: https://doi.org/10.1212/wnl.57.4.722
dc.relation
Neurology, 2001, vol. 57, num. 4, p. 722-724
dc.relation
https://doi.org/10.1212/wnl.57.4.722
dc.rights
(c) American Academy of Neurology, 2001
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Ciències Clíniques)
dc.subject
Líquid cefalorraquidi
dc.subject
Esclerosi múltiple
dc.subject
Proteïna-tirosina-fosfatasa
dc.subject
Cerebrospinal fluid
dc.subject
Multiple sclerosis
dc.subject
Protein-tyrosine phosphatase
dc.title
14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
